KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to -$33.2 million.

  • Rigel Pharmaceuticals' Cash from Investing Activities fell 972.57% to -$33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.9 million, marking a year-over-year decrease of 1053.70%. This contributed to the annual value of $4.1 million for FY2024, which is 196.11% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$33.2 million for Q3 2025, which was down 42.53% from -$23.3 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $22.6 million during Q1 2022, with a 5-year trough of -$49.7 million in Q2 2021.
  • In the last 3 years, Rigel Pharmaceuticals' Cash from Investing Activities had a median value of -$1.2 million in 2023 and averaged -$6.1 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Cash from Investing Activities spiked by 424.96% in 2024, and later crashed by 3,471.25% in 2025.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Cash from Investing Activities stood at $6.5 million in 2021, then surged by 186.65% to $18.6 million in 2022, then slumped by 136.96% to -$6.9 million in 2023, then crashed by 58.77% to -$10.9 million in 2024, then plummeted by 972.57% to -$33.2 million in 2025.
  • Its Cash from Investing Activities stands at -$33.2 million for Q3 2025, versus -$23.3 million for Q2 2025 and -$10.6 million for Q1 2025.